Shots: Voyager to receive $30M up front, $20M as exercise fees for 2 options (exercisable within 12mos.) & ~$580M as development, regulatory & commercial milestones related to licensed products including […]readmore
Shots: Selecta to receive up front and ~$1.124B upon the achievement of development or commercial milestones or Takeda’s election continue its activities at specified development stages. Selecta is also eligible […]readmore
Shots: Xencor to receive $100M up front, $25M as an equity investment, ~$1.18B in milestones along with royalties on net sales of products that emerge from the collaboration. The transaction […]readmore
Shots: The companies terminated their collaboration that centered around bintrafusp alfa as the drug failed to show potential in INTR@PID Lung 037 study as the 2L treatment for metastatic BTC […]readmore
Shots: Union to receive $20M up front and is eligible to receive ~$247M in milestone along with royalties on sales of orismilast in China & holds the global rights for […]readmore
Shots: Intract to receive an up front, development & commercial milestone along with royalties on product sales. Bio-Thera gets global license to Intract’s Soteria & Phloral oral drug delivery platform […]readmore
Shots: VaxEquity can receive ~$195M in development, approval, and sales-based milestones along with royalties per program & is also eligible to receive an equity investment from AstraZeneca for the development […]readmore
Shots: The companies collaborated to evaluate IMU-838 (DHODH inhibitors) + NHC (nucleoside analogues) to treat patients with viral infections including COVID-19 and Influenza The preclinical research showed that IMU-838 strongly […]readmore
Shots: Everest to get the rights to develop & commercialize Abs resulting from the collaboration. AbCellera to receive research payments and is eligible to receive clinical and commercial milestones along […]readmore
Shots: The acquisition expands Novartis’ ophthalmology portfolio with the addition of Arctos’ pre-clinical optogenetics-based AAV gene therapy program and its technology The acquisition marks the Novartis commitment to identify optogenetics-based […]readmore